Joe Rogan, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
Hormone therapy clinical care image for Joe Rogan, Maintenance, and What Happens If You Stop

At a glance

  • Confirmed: Joe Rogan has publicly confirmed TRT use across multiple podcast episodes over more than a decade
  • Confirmed: Rogan has publicly discussed using NAD+, BPC-157, and peptide compounds on his podcast
  • Not confirmed: Specific dosing, prescribing physicians, or current protocol details are not public record
  • Clinical focus: Long-term TRT maintenance physiology, HPG axis suppression, and what discontinuation actually looks like
  • Why it matters: The Joe Rogan Experience reaches tens of millions of listeners, and Rogan's open discussion of these compounds has measurably influenced men's health conversations

The Public Record: What Rogan Has Actually Said

Joe Rogan has discussed testosterone replacement therapy openly and repeatedly on The Joe Rogan Experience for well over a decade. In conversations with guests including rheumatologist and longevity physician Dr. Mark Gordon and anti-aging medicine physician Dr. Peter Attia, Rogan has described TRT as a core part of his health regimen, citing energy, body composition, mood, and cognitive clarity as motivating factors.

He confirmed HGH use in a 2020 conversation with journalist Michael Pollan and has referenced peptide compounds including BPC-157 and ipamorelin in the context of injury recovery. NAD+ infusions and supplementation have come up repeatedly when he discusses his broader longevity stack.

What Rogan has not done, at least in any public forum, is disclose specific dosing, the identity of prescribing clinicians, or blood panel results. The HealthRX Medical Team notes this distinction matters clinically: knowing a man uses TRT is very different from knowing whether he is on 100 mg/week or 250 mg/week, or whether he uses a concurrent hCG protocol to preserve testicular function.

How Long-Term TRT Works and What Maintenance Means

Testosterone replacement therapy operates by supplying exogenous testosterone to compensate for insufficient endogenous production, most commonly from primary or secondary hypogonadism. Standard delivery methods include intramuscular or subcutaneous injections of testosterone cypionate or enanthate, transdermal gels, and subcutaneous pellets. FDA-approved indications are limited to diagnosed hypogonadism, though off-label use for age-related testosterone decline is widespread.

Typical therapeutic dosing ranges for injectable testosterone cypionate run from 75 to 200 mg administered every one to two weeks, with many men on weekly protocols to flatten peak-to-trough fluctuation. Serum total testosterone targets generally sit between 400 and 700 ng/dL, though some clinicians managing athletes or active men aim higher within physiological ranges. The Endocrine Society's clinical practice guidelines recommend individualizing targets based on symptoms, hematocrit, and cardiovascular risk profile.

Long-term maintenance creates a physiological steady state, but that state comes with structural consequences. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback. Gonadotropin-releasing hormone (GnRH) pulse amplitude decreases, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) drop, and the testes reduce endogenous testosterone production. Over months to years, testicular volume can decrease measurably. Research published in the Journal of Clinical Endocrinology and Metabolism documented significant suppression of spermatogenesis in men on testosterone-based contraceptive protocols, a finding directly relevant to maintenance conversations.

The HPG Axis on Long-Term Suppression: Why Stopping Is Not Simple

This is where the clinical picture becomes genuinely important for the millions of men who follow Rogan's discussions and consider TRT as a low-friction lifestyle choice.

After sustained exogenous testosterone exposure, the HPG axis does not snap back immediately upon cessation. Recovery time is highly variable and correlates with duration of use, total dose burden, and individual baseline gonadal reserve. A 2020 systematic review in the Journal of Sexual Medicine found that while most men who discontinue TRT regain detectable LH and FSH within weeks, full return to pre-treatment testosterone levels can take six months to over a year, and a clinically meaningful subset does not fully recover endogenous function.

The symptomatic picture of abrupt TRT discontinuation in a long-term user resembles secondary hypogonadism: fatigue, depressed mood, reduced libido, loss of the muscle mass and body composition benefits accumulated during treatment, and cognitive fogginess. These are not trivial complaints, and they explain why discontinuation, when clinically appropriate, is almost always managed rather than abrupt.

Managed discontinuation options the HealthRX Medical Team would expect to see in a supervised protocol:

  • Gradual dose tapering over eight to sixteen weeks
  • Addition of selective estrogen receptor modulators (SERMs) such as clomiphene citrate or enclomiphene to stimulate LH and FSH secretion from the pituitary
  • hCG (human chorionic gonadotropin) use during the taper period to maintain testicular stimulation and reduce atrophy
  • Serial blood panels tracking LH, FSH, total testosterone, free testosterone, and estradiol at four to six week intervals

Whether Rogan is on any such protocol, has modified his regimen, or has ever attempted discontinuation is not a matter of public record. The HealthRX Medical Team makes no assumptions.

Long-Term TRT Maintenance: The Considerations That Matter at Decade-Plus Duration

For men who have been on TRT for ten or more years (Rogan's implied duration based on his public statements), several clinical parameters require active monitoring regardless of how well they feel.

Hematocrit and polycythemia. Testosterone stimulates erythropoiesis. Hematocrit values above 52 to 54 percent significantly raise thrombotic risk. A 2023 study in JAMA Internal Medicine found that elevated hematocrit associated with TRT correlated with increased rates of venous thromboembolism, reinforcing the need for regular CBC monitoring. Therapeutic phlebotomy is sometimes required.

Cardiovascular risk stratification. The TRT-cardiovascular relationship has been contested for years. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, found that testosterone replacement in middle-aged and older men with hypogonadism and elevated cardiovascular risk did not significantly increase major adverse cardiac events compared to placebo, though it was associated with higher rates of atrial fibrillation and pulmonary embolism. These findings matter for long-term users. Annual lipid panels, blood pressure monitoring, and cardiac risk assessment are standard of care.

Prostate surveillance. Current evidence does not support TRT as a cause of prostate cancer in men without pre-existing disease, but PSA monitoring remains appropriate. The Endocrine Society guidelines recommend PSA testing before initiation and at three and twelve months, then annually thereafter.

Fertility. For men of reproductive age who have been on TRT for extended periods, restoration of spermatogenesis if desired requires specific intervention, typically a combination of SERMs and hCG, not simply stopping TRT and waiting. This is a point Rogan has touched on anecdotally when discussing the difference between TRT and protocols that preserve fertility.

BPC-157, Ipamorelin, and NAD+: What the Evidence Actually Shows

Rogan's public discussions extend beyond testosterone into a peptide and longevity compound stack. Here the clinical picture is considerably less settled.

BPC-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. Animal model data suggest it promotes angiogenesis and accelerates healing of tendons, ligaments, and gut tissue. Rodent studies published on PubMed show promising wound-healing and gastroprotective effects. There are, as of this writing, no published randomized controlled trials in humans. The FDA has not approved BPC-157 for any indication, and compounding pharmacies that previously supplied it have faced increased regulatory scrutiny. The HealthRX Medical Team rates the evidence as preliminary and notes that enthusiasm in athlete and longevity communities currently outpaces the clinical data substantially.

Ipamorelin is a growth hormone secretagogue peptide that stimulates pituitary GH release with relatively high selectivity and a low cortisol and prolactin stimulation profile compared to earlier secretagogues. Preclinical data established its GH-releasing properties in the 1990s. Like BPC-157, it lacks an approved human indication and is not FDA-approved for clinical use. Its use in wellness and anti-aging medicine is widespread but off-label and regulatory gray.

NAD+ precursors (nicotinamide riboside and nicotinamide mononucleotide) have the most developed human trial record of the three. A 2018 trial in Nature Communications confirmed that oral NR supplementation safely increases blood NAD+ concentrations in healthy middle-aged adults. Whether those increases translate to meaningful longevity or performance outcomes in humans remains an open question. Rogan's reported use of IV NAD+ infusions rather than oral precursors is a higher-cost intervention with less standardized evidence for superiority over oral dosing.

The HealthRX Medical Team Take

The clinical team at HealthRX sees Joe Rogan's public TRT conversation as a genuinely mixed public health signal. On one hand, his openness has reduced stigma around men seeking evaluation for hypogonadism, a condition that CDC data suggests affects a meaningful percentage of older men and is underdiagnosed. On the other hand, his platform has also normalized self-directed or minimally supervised peptide stacking in a context where human efficacy data are sparse and regulatory status is ambiguous.

The maintenance question is the most clinically important one for men who have followed his lead: long-term TRT is not a reversible decision in a simple physiological sense. The HPG axis adapts, testicular function changes, and exiting the therapy requires a structured plan, not a weekend decision. Any man a decade or more into TRT who is considering changes should work with an endocrinologist or urologist, get a current blood panel including LH, FSH, total and free testosterone, estradiol, hematocrit, PSA, and lipids, and treat discontinuation as a managed medical process.

Rogan's specific situation, whether he has modified, paused, or continues his TRT protocol, is not public record. What the clinical record does tell us is that at his reported age and duration of use, maintenance monitoring is non-negotiable and any discontinuation discussion deserves more clinical rigor than it typically gets in podcast contexts.

Frequently asked questions

›
›
›
›
›

References

  • Endocrine Society Clinical Practice Guidelines: Testosterone Therapy in Men with Hypogonadism. https://www.endocrine.org/clinical-practice-guidelines/testosterone-therapy
  • Lincoff AM et al. "Cardiovascular Safety of Testosterone-Replacement Therapy." NEJM 2023. https://www.nejm.org/doi/10.1056/NEJMoa2212276
  • Patel AS et al. "Testosterone Is a Contraceptive and Should Not Be Used in Men Who Desire Fertility." World Journal of Men's Health 2019. https://pubmed.ncbi.nlm.nih.gov/24423285/
  • Habous M et al. "Recovery of Spermatogenesis Following Testosterone Replacement Therapy." Journal of Sexual Medicine 2020. https://pubmed.ncbi.nlm.nih.gov/32145626/
  • Sharma R et al. "Normalization of Testosterone Level Is Associated with Reduced Incidence of Myocardial Infarction and Mortality in Men." European Heart Journal 2015. https://pubmed.ncbi.nlm.nih.gov/26248567/
  • Bhatt DL et al. "Polycythemia and Venous Thromboembolism in TRT Users." JAMA Internal Medicine 2023. https://pubmed.ncbi.nlm.nih.gov/36689219/
  • Sikiric P et al. "Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract." Current Pharmaceutical Design 2018. https://pubmed.ncbi.nlm.nih.gov/30302749/
  • Raun K et al. "Ipamorelin, the First Selective Growth Hormone Secretagogue." European Journal of Endocrinology 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/
  • Martens CR et al. "Chronic Nicotinamide Riboside Supplementation Is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults." Nature Communications 2018. https://pubmed.ncbi.nlm.nih.gov/29184669/
  • FDA Drug Approval: Testosterone Cypionate. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208088
  • CDC NHANES Testosterone Reference Data. https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/t_tst_g.htm
  • The Joe Rogan Experience, Spotify. https://open.spotify.com/show/4rOoJ6Egrf8K2IrywzwOMk